FDA Approves Eflapegrastim for Chemo-Induced Neutropenia

On September 9, 2022, the U.S. Food and Drug Administration (FDA) approved eflapegrastim-xnst to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with nonmyeloid malignancies who are receiving myelosuppressive treatment.

For more information, read the Spectrum Pharmaceuticals announcement.

Posted 9/12/2022